Evotec Ag Stock Price, News & Analysis

Evotec has launched E.MPD, a global molecular patient database, aimed at enhancing drug development through AI and machine learning technologies. The initiative is part of Evotec's strategy to increase the probability of success (PoS) in therapeutics research. The company confirmed its goals for Action Plan 2025 and announced the appointment of Dr. Matthias Evers as Chief Business Officer to lead business development. Evotec is focused on establishing itself as a leader in precision medicine, leveraging partnerships and innovative technologies.

Evotec announced a collaboration with the University of Bristol to enhance its molecular patient database focusing on nephrotic syndrome. This partnership grants Evotec access to an international cohort's longitudinal clinical data and biospecimens from hundreds of patients across Asia, India, and Africa. Evotec plans to utilize its multi-omics platforms, EVO panOmics and EVO panHunter, to identify disease mechanisms and diagnostic markers, aiming for new targeted therapies. This collaboration could significantly impact treatment options for nephrotic syndrome patients.

Evotec SE (NASDAQ: EVO) has made an equity investment in IMIDomics, Inc., a biotechnology firm focusing on treatments for immune-mediated inflammatory diseases (IMIDs). The investment will allow Evotec to participate in IMIDomics' board of directors while supporting the advancement of its Precision Discovery™ Engine. This initiative integrates patient biological data and clinical expertise to identify effective treatments for over 17,000 IMID patients. The collaboration aims to develop targeted medicines addressing unmet medical needs in the field.

Evotec SE announced that Bayer has discontinued the development of eliapixant (BAY1817080), an investigational P2X3 receptor antagonist. Bayer determined that the risks outweigh the benefits after reviewing the available data. As a result, Evotec regains rights to all P2X3 assets and will evaluate the data and options moving forward. The company states that this change does not affect its strategic goals outlined in the Action Plan 2025.

Evotec SE announced a partnership with Boehringer Ingelheim focusing on induced pluripotent stem cell (iPSC)-based disease modeling for ophthalmologic disorders. This collaboration aims to identify and validate therapeutic targets through phenotypic screening and Evotec's PanOmics platform, addressing a significant unmet need in vision-related diseases. The partnership includes undisclosed upfront payments and ongoing royalties for successful therapeutic development. Dr. Cord Dohrmann highlighted the potential of their unique methodologies to deliver effective drugs.

Evotec SE has announced a drug discovery collaboration with Eli Lilly focusing on metabolic diseases, particularly kidney diseases and diabetes. This partnership will leverage Evotec's extensive kidney disease patient database and metabolic expertise to identify novel therapeutic targets. Over three years, Lilly can select up to five programs, potentially generating up to $1 billion in total value for Evotec, including milestone payments and royalties. This collaboration underscores Evotec's commitment to innovative drug development in underserved therapeutic areas.

Evotec has expanded its collaboration with Bristol Myers Squibb to target neurodegenerative diseases like Alzheimer's through a novel protein degradation strategy. This expansion includes a payment of US$ 15 million from Bristol Myers Squibb. The partnership, initiated in December 2016, aims to discover disease-modifying treatments using Evotec's advanced patient-derived disease models. Dr. Cord Dohrmann highlighted the collaboration's productivity and commitment to innovative drug targeting mechanisms, addressing the significant unmet medical need in treating neurodegenerative conditions.

Evotec announced it has received a €7.5 million grant from the German Federal Ministry of Education and Research to develop EVT075, a potential first-in-class immunomodulatory therapy targeting COVID-19. This funding aims to facilitate clinical studies assessing the safety and efficacy of the compound, which has shown promising results against SARS-CoV-2 in pre-clinical studies. The therapy aims to amplify the immune response and reduce hospitalizations related to COVID-19.

Evotec SE has received an $18 million grant from the Bill & Melinda Gates Foundation to support a fully integrated drug discovery program targeting women's health and contraceptive technology. The project will utilize Evotec's advanced drug discovery platforms and AI/ML tools to develop a first-in-class program, taking it from concept to pre-clinical development. Dr. Craig Johnstone, COO of Evotec, expressed excitement about the potential impact of the project on women's health and the trust placed in their capabilities by the Gates Foundation.